摘要
目的探讨美洛西林钠舒巴坦钠治疗肺炎治疗效果。方法选择2010年2月—2012年4月该院收治的108例肺炎患者,并随机分为观察组(54例)与对照组两组(54例),观察组给予美洛西林钠舒巴坦钠,静脉滴注,2次/d,对照组给予美洛西林钠,静脉滴注,2次/d,两组均以14d为一治疗疗程。结果观察组、对照组治疗总有效率分别为88.8%,66.6%,观察组显著优于对照组,且两组差异性显著,因而具有统计学意义标准(P<0.05)。观察组1例出现不良反应,对照组2例,比较两组不良反应发生率,无显著性差异,因而不具有统计学意义标准(P>0.05)。结论美洛西林钠舒巴坦钠治疗肺炎优于单纯美洛西林钠。安全性高,治疗效果确切,值得推广。
Objective To investigate the therapeutic effect of mezlocillin sodium and Sulbactam Sodium for the treatment of pneumonia merlot. Methods 108 cases of patients with pneumonia in 2010 February to 2012 April in our hospital, and randomly divided into observation group （54 cases） and control group （54 cases）, two groups of observation group were treated with mezlocillin sodium and Sulbactam Sodium for injection, intravenous drip,2 times/day, while the control group was given intravenous mezlocillin sodium, 2 times/day, two groups were in 14d for a course of treatment. Results The observation group, the control group total effective rate were 88.8%, 66.6%, the observation group was ~ignificantly better than the control group, and the differences between the two groups was significant, so it has statistical significance（P〈0.05） standard. The observation group of 1 cases of adverse reactions, 2 cases in the control group, the incidence of adverse reaction were compared between the two groups, no significant difference, which was not statistically significant （P〉0.05 standard）. Conclusion Mezlocillin sodium and Sulbactam Sodium for treatment of pneumonia is better than that of mezlocillin sodium. High safety, exact curative effect, is worth popularizing.
出处
《中国卫生产业》
2013年第17期9-9,11,共2页
China Health Industry
关键词
肺炎
美洛西林钠舒巴坦钠
疗效
Mezlocillin sodium and Sulbactam Sodium for injection
Pneumonia
Curative effect
